Press Releases

Date Title
Jun 11, 2024 Illumina DRAGEN v4.3 powers most comprehensive, accurate genome with industry-leading innovations
Jun 4, 2024 Illumina launches latest chemistry across most popular mid-throughput sequencers, enabling higher quality and greater speed for customers at lower cost
Jun 3, 2024 Illumina Board of Directors approves spin-off of GRAIL; declares spin-off dividend of GRAIL shares
Jun 3, 2024 Illumina appoints Everett Cunningham Chief Commercial Officer
May 29, 2024 Illumina drives genomic testing as standard of care in oncology through collaborative research presented at ASCO
May 28, 2024 Illumina releases 2023 Corporate Social Responsibility Report
May 20, 2024 Anna Richo joins Illumina's Board of Directors
May 15, 2024 Illumina To Webcast Upcoming Investor Conference
May 6, 2024 Illumina publicly files Form 10 registration statement ahead of planned divestiture of GRAIL
May 3, 2024 Illumina To Webcast Upcoming Investor Conference
May 2, 2024 Illumina Reports Financial Results for First Quarter of Fiscal Year 2024
Apr 12, 2024 Illumina's planned divestment of GRAIL approved by the European Commission
Apr 9, 2024 Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer
Apr 4, 2024 Illumina to Announce First Quarter 2024 Financial Results on Thursday, May 2, 2024
Feb 8, 2024 Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2023
Jan 9, 2024 Illumina Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2023
Jan 5, 2024 Illumina expands collaboration with Janssen to advance molecular residual disease cancer test
Jan 4, 2024 Illumina to Announce Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 8, 2024
Jan 4, 2024 The Alliance for Genomic Discovery welcomes Bristol Myers Squibb, GSK, and Novo Nordisk